PL2780370T3 - Przeciwciało przeciwko adrenomedulinie (adm) lub fragment przeciwciała przeciwko adp lub szkielet przeciwko adm inny niż ig do zastosowania do stabilizacji krążenia w terapii ostrej choroby lub ostrego stanu pacjenta - Google Patents
Przeciwciało przeciwko adrenomedulinie (adm) lub fragment przeciwciała przeciwko adp lub szkielet przeciwko adm inny niż ig do zastosowania do stabilizacji krążenia w terapii ostrej choroby lub ostrego stanu pacjentaInfo
- Publication number
- PL2780370T3 PL2780370T3 PL12784632T PL12784632T PL2780370T3 PL 2780370 T3 PL2780370 T3 PL 2780370T3 PL 12784632 T PL12784632 T PL 12784632T PL 12784632 T PL12784632 T PL 12784632T PL 2780370 T3 PL2780370 T3 PL 2780370T3
- Authority
- PL
- Poland
- Prior art keywords
- adm
- antibody
- acute
- adrenomedullin
- scaffold
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11189449 | 2011-11-16 | ||
| EP12160016 | 2012-03-16 | ||
| PCT/EP2012/072932 WO2013072513A1 (en) | 2011-11-16 | 2012-11-16 | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation |
| EP12784632.7A EP2780370B1 (en) | 2011-11-16 | 2012-11-16 | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2780370T3 true PL2780370T3 (pl) | 2020-01-31 |
Family
ID=48429016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12784632T PL2780370T3 (pl) | 2011-11-16 | 2012-11-16 | Przeciwciało przeciwko adrenomedulinie (adm) lub fragment przeciwciała przeciwko adp lub szkielet przeciwko adm inny niż ig do zastosowania do stabilizacji krążenia w terapii ostrej choroby lub ostrego stanu pacjenta |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9402900B2 (pl) |
| EP (1) | EP2780370B1 (pl) |
| JP (1) | JP6224608B2 (pl) |
| AU (1) | AU2012338733B2 (pl) |
| CA (1) | CA2856142A1 (pl) |
| DK (1) | DK2780370T3 (pl) |
| ES (1) | ES2751492T3 (pl) |
| HR (1) | HRP20191771T1 (pl) |
| HU (1) | HUE045940T2 (pl) |
| LT (1) | LT2780370T (pl) |
| PL (1) | PL2780370T3 (pl) |
| PT (1) | PT2780370T (pl) |
| SG (1) | SG11201402358RA (pl) |
| WO (1) | WO2013072513A1 (pl) |
| ZA (1) | ZA201403549B (pl) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3082858T3 (pl) * | 2013-12-20 | 2021-09-27 | Angiobiomed Gmbh | Środek wiążący adrenomedulinę do zastosowania w terapii nowotworu |
| US11076813B2 (en) * | 2016-07-22 | 2021-08-03 | Edwards Lifesciences Corporation | Mean arterial pressure (MAP) derived prediction of future hypotension |
| EP3339324A1 (en) | 2016-12-22 | 2018-06-27 | sphingotec GmbH | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof |
| JP7727371B2 (ja) * | 2016-12-16 | 2025-08-21 | アドレノメト アクチェンゲゼルシャフト | うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場 |
| HRP20241795T1 (hr) | 2017-09-25 | 2025-03-14 | Adrenomed Ag | Anti-adrenomedulin (adm) – vezujući entitet za uporabu u terapiji ili prevenciji simptoma bolesti |
| WO2019077082A1 (en) | 2017-10-18 | 2019-04-25 | Adrenomed Ag | SURVEILLANCE OF THERAPY UNDER TREATMENT WITH ANTI-ADRENOMEDULIN BINDER (ADM) |
| EP3871689A1 (en) | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
| US20230250166A1 (en) | 2020-02-27 | 2023-08-10 | Adrenomed Ag | Anti-adrenomedullin (adm) binder for use in therapy of patients in shock |
| US20230193348A1 (en) | 2020-02-27 | 2023-06-22 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock |
| CN115244080A (zh) * | 2020-02-27 | 2022-10-25 | 艾德里诺医药公司 | 用于治疗或预防休克的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig支架 |
| AU2021238591A1 (en) | 2020-03-16 | 2022-11-17 | Adrenomed Ag | Pro-Adrenomedullin or fragment thereof in patients infected with Corona virus and treatments with binder against adrenomedullin |
| CA3254142A1 (en) | 2022-03-15 | 2023-09-21 | Adrenomed Ag | STABLE AQUEOUS FORMULATION OF AN ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR AN ANTI-ADM ANTIBODY FRAGMENT |
| AU2023315168A1 (en) | 2022-07-29 | 2025-02-13 | 4TEEN4 Pharmaceuticals GmbH | Prediction of an increase of dpp3 in a patient with septic shock |
| AU2023313376A1 (en) | 2022-07-29 | 2025-03-06 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
| EP4345109A1 (en) | 2022-09-30 | 2024-04-03 | AdrenoMed AG | Anti-adrenomedullin (adm) binder for use in therapy of pediatric patients with congenital heart disease |
| WO2026046978A1 (en) | 2024-08-26 | 2026-03-05 | Pam Theragnostics Gmbh | Anti-adm antibodies, anti-adm antibody fragment or anti-adm non-ig scaffold for therapy or prevention of immune effector cell therapy side effects |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| AU634716B2 (en) | 1988-08-01 | 1993-03-04 | Ciba Corning Diagnostics Corp. | Method for detection of an analyte using acridinium esters and liposomes |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| JP2774769B2 (ja) | 1993-04-26 | 1998-07-09 | 賢治 寒川 | アドレノメデュリン |
| DE69602756T2 (de) | 1995-08-18 | 2000-02-10 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Rockville | Funktionelle rolle von adrenomedullin(am) und dem gen-verwandten produkt(pamp) in der menschlichen pathologie und physiologie |
| CA2242308A1 (en) | 1997-12-08 | 1999-06-08 | Smithkline Beecham Laboratoires Pharmaceutiques | Novel compounds |
| DE19847690A1 (de) | 1998-10-15 | 2000-04-20 | Brahms Diagnostica Gmbh | Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| WO2001018550A2 (en) | 1999-09-10 | 2001-03-15 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Determination of adrenomedullin-binding proteins |
| EP1322957B1 (en) | 2001-05-04 | 2009-08-12 | Biosite Incorporated | Diagnostic markers of acute coronary syndromes and methods of use thereof |
| AU2002323501C1 (en) | 2001-08-30 | 2010-04-29 | Biorexis Technology, Inc | Modified transferrin fusion proteins |
| US6864237B2 (en) | 2002-05-17 | 2005-03-08 | Ping Wang | Treatment of shock using adrenomedullin and adrenomedullin binding protein-1 |
| ES2348230T3 (es) | 2002-06-07 | 2010-12-01 | Dyax Corp. | Prevención y reducción de la isquemia. |
| DE10316583A1 (de) | 2003-04-10 | 2004-10-28 | B.R.A.H.M.S Aktiengesellschaft | Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung |
| EP1620734A1 (en) | 2003-04-25 | 2006-02-01 | Genova Ltd. | Secreted polypeptide species reduced cardiovascular disorders |
| US6884781B2 (en) | 2003-05-16 | 2005-04-26 | Ping Wang | Treatment of shock using adrenomedullin binding protein-1 |
| US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| US20070280886A1 (en) | 2004-09-09 | 2007-12-06 | Bayer Healthcare Ag | Diagnostics and Therapeutics for Diseases Associated with Adrenomedullin Receptor (Amdr) |
| AU2005287557B2 (en) | 2004-09-21 | 2011-10-13 | Biontech Ag | Use of microproteins as tryptase inhibitors |
| US9829494B2 (en) | 2005-12-01 | 2017-11-28 | Adrenomed Ag | Methods of treatment using ADM antibodies |
| US8633297B2 (en) * | 2007-10-31 | 2014-01-21 | Medimmune, Llc | Protein scaffolds |
| ES2373832T3 (es) | 2007-12-19 | 2012-02-09 | Affibody Ab | Polipéptido derivado de proteína a y capaz de unirse a pdgf. |
| BRPI0921469B1 (pt) | 2008-11-03 | 2022-01-18 | Molecular Partners Ag | Proteínas de ligação que inibem a interação com o receptor de vegf-a, composição farmacêutica |
| MX2012002428A (es) | 2009-08-27 | 2012-09-12 | Covagen Ag | Compuestos de union il-17 y usos medicos de los mismos. |
| RU2553333C2 (ru) | 2009-12-14 | 2015-06-10 | Сцил Протеинс Гмбх | Способ идентификации гетеромультимерных модифицированных убиквитиновых белков со способностью связываться с лигандами |
| DE102010040035A1 (de) | 2010-03-04 | 2011-09-08 | Robert Bosch Gmbh | Verbesserungen der Rückwärts-Analyse zur Bestimmung von Fehlermaskierungsfaktoren |
| PL2580236T3 (pl) | 2010-06-08 | 2019-09-30 | Pieris Pharmaceuticals Gmbh | Muteiny lipokaliny łez wiążące IL-4 R alfa |
| FR2964103B1 (fr) | 2010-08-30 | 2018-11-23 | Universite D'aix-Marseille | Anticorps se liant a l'adrenomedulline et aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament |
| HRP20170427T1 (hr) | 2011-11-16 | 2017-06-16 | Sphingotec Gmbh | Testovi na adrenomedulin i postupci određivanja zrelog adrenomedulina |
-
2012
- 2012-11-16 EP EP12784632.7A patent/EP2780370B1/en active Active
- 2012-11-16 JP JP2014541697A patent/JP6224608B2/ja active Active
- 2012-11-16 AU AU2012338733A patent/AU2012338733B2/en active Active
- 2012-11-16 PT PT127846327T patent/PT2780370T/pt unknown
- 2012-11-16 ES ES12784632T patent/ES2751492T3/es active Active
- 2012-11-16 CA CA2856142A patent/CA2856142A1/en active Pending
- 2012-11-16 HR HRP20191771TT patent/HRP20191771T1/hr unknown
- 2012-11-16 LT LT12784632T patent/LT2780370T/lt unknown
- 2012-11-16 HU HUE12784632A patent/HUE045940T2/hu unknown
- 2012-11-16 SG SG11201402358RA patent/SG11201402358RA/en unknown
- 2012-11-16 PL PL12784632T patent/PL2780370T3/pl unknown
- 2012-11-16 US US14/358,506 patent/US9402900B2/en active Active
- 2012-11-16 WO PCT/EP2012/072932 patent/WO2013072513A1/en not_active Ceased
- 2012-11-16 DK DK12784632T patent/DK2780370T3/da active
-
2014
- 2014-05-15 ZA ZA2014/03549A patent/ZA201403549B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2751492T3 (es) | 2020-03-31 |
| CA2856142A1 (en) | 2013-05-23 |
| JP6224608B2 (ja) | 2017-11-01 |
| ZA201403549B (en) | 2022-11-30 |
| SG11201402358RA (en) | 2014-06-27 |
| US9402900B2 (en) | 2016-08-02 |
| EP2780370A1 (en) | 2014-09-24 |
| LT2780370T (lt) | 2019-11-25 |
| NZ624876A (en) | 2016-08-26 |
| AU2012338733A1 (en) | 2014-05-29 |
| AU2012338733B2 (en) | 2017-08-24 |
| HRP20191771T1 (hr) | 2019-12-27 |
| HUE045940T2 (hu) | 2020-01-28 |
| WO2013072513A1 (en) | 2013-05-23 |
| PT2780370T (pt) | 2019-10-30 |
| DK2780370T3 (da) | 2019-10-28 |
| EP2780370B1 (en) | 2019-09-25 |
| US20140322225A1 (en) | 2014-10-30 |
| JP2015502349A (ja) | 2015-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201403549B (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation | |
| ZA201403548B (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy | |
| SG11201402362VA (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition | |
| HRP20181378T1 (hr) | Postupci liječenja pedijatrijskih pacijenata deksmedetomidinom | |
| EP2790725A4 (en) | METHOD FOR IMPROVING MEDICAL THERAPIES | |
| MY174894A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation | |
| IL233313A0 (en) | Composition of novel carbohydrate drug for treatment of human diseases | |
| HUE045367T2 (hu) | Kombinált terápia diabétesz kezelésére | |
| ZA201403550B (en) | Anti-adrenomedullin (adm) antibody of anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease | |
| ZA201501390B (en) | Compounds for the treatment of mtor pathway related diseases | |
| IL260078B (en) | Therapy used to treat Gaucher disease | |
| IL230960A0 (en) | A device for the treatment of eye disease | |
| IL230959A0 (en) | A device for the treatment of eye disease | |
| BR112013013242A2 (pt) | aparelho de tratamento de sangue extracorpóreo | |
| GB201002224D0 (en) | Respiratory disease treatment | |
| IL275636A (en) | Medical combination for cancer treatment | |
| EP2601954A4 (en) | THERAPEUTIC FOR DISEASES | |
| ZA201308176B (en) | Therapeutic treatment | |
| BR112014006593A2 (pt) | dispositivo médico para inserção no corpo humano | |
| IL228891A (en) | 3-carboxylic salts-n-ethyl n, n-dimethylpropane-1-amine for use in the treatment of cardiovascular disease | |
| ZA201306759B (en) | Compounds for use in imaging,diagnosing and/or treatment of diseases of the central nervous system | |
| GB201002235D0 (en) | Respiratory disease treatment | |
| GB201001893D0 (en) | Respiratory disease treatment | |
| GB201001903D0 (en) | Respiratory disease treatment | |
| EP2900832A4 (en) | PROCEDURE FOR THE ADOPTION OF A MEDICAMENT FOR INHIBITING CHOLESTERAL ABSORPTION TO A PATIENT |